Crescent Biopharma, Inc. SEC filings CBIO

Crescent Biopharma, Inc. has 676 filings in SEC EDGAR's recent list, going back to Jul 10, 2003. Its latest annual report, Form 10-K, was filed on Feb 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 30, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (other events). The company's fiscal year ends on December 31.

Crescent Biopharma, Inc. SEC filings
Form Description Filed Period
SCHEDULE 13G Ownership over 5% (passive) Oct 27, 2026 —
8-K Current report
Other events
Oct 15, 2026 Oct 15, 2026
4 Insider transaction Sep 18, 2026 Sep 16, 2026
4 Insider transaction Sep 18, 2026 Sep 16, 2026
4 Insider transaction Sep 18, 2026 Sep 16, 2026
4 Insider transaction Sep 18, 2026 Sep 16, 2026
4 Insider transaction Sep 18, 2026 Sep 16, 2026
4 Insider transaction Sep 18, 2026 Sep 16, 2026
4 Insider transaction Sep 18, 2026 Sep 16, 2026
S-8 Employee stock plan registration Sep 18, 2026 —
144 Notice of proposed sale Sep 17, 2026 —
144 Notice of proposed sale Sep 17, 2026 —
144 Notice of proposed sale Sep 16, 2026 —
144 Notice of proposed sale Sep 16, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2026 —
EFFECT Filing Jul 31, 2026 —
POS AM Filing Jul 30, 2026 —
424B3 Prospectus Jul 30, 2026 —
10-Q Quarterly report Jul 30, 2026 Jun 30, 2026
8-K Current report
Results of operations
Jul 30, 2026 Jul 30, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Jul 20, 2026 —
4 Insider transaction Jul 20, 2026 Jul 16, 2026
8-K Current report
Other events
Jul 15, 2026 Jul 14, 2026
424B5 Prospectus supplement Jul 15, 2026 —
8-K Current report
Results of operations
Jul 14, 2026 Jul 14, 2026
424B5 Prospectus supplement Jul 14, 2026 —
EFFECT Filing Jul 10, 2026 —
S-3 Shelf registration Jul 1, 2026 —
4 Insider transaction Jun 23, 2026 Jun 22, 2026
4 Insider transaction Jun 23, 2026 Jun 22, 2026
4 Insider transaction Jun 23, 2026 Jun 22, 2026
4 Insider transaction Jun 23, 2026 Jun 22, 2026
4 Insider transaction Jun 23, 2026 Jun 22, 2026
4 Insider transaction Jun 23, 2026 Jun 22, 2026
4 Insider transaction Jun 23, 2026 Jun 22, 2026
424B3 Prospectus Jun 22, 2026 —
10-Q/A Amended quarterly report Jun 22, 2026 Mar 31, 2026
4 Insider transaction Jun 3, 2026 Jun 2, 2026
4 Insider transaction Jun 3, 2026 Jun 2, 2026
4 Insider transaction Jun 3, 2026 Jun 2, 2026
4 Insider transaction Jun 3, 2026 Jun 2, 2026
4 Insider transaction Jun 3, 2026 Jun 2, 2026
8-K Current report
Shareholder vote results
Jun 3, 2026 Jun 2, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
SCHEDULE 13G Ownership over 5% (passive) May 15, 2026 —
424B3 Prospectus Apr 29, 2026 —
8-K Current report
Results of operations
Apr 29, 2026 Apr 29, 2026
10-Q Quarterly report Apr 29, 2026 Mar 31, 2026
DEFA14A Additional proxy material Apr 21, 2026 —
DEFA14A Additional proxy material Apr 21, 2026 —
DEF 14A Proxy statement Apr 21, 2026 Jun 2, 2026
424B3 Prospectus Mar 17, 2026 —
EFFECT Filing Mar 3, 2026 —
POS AM Filing Mar 3, 2026 —
424B3 Prospectus Feb 26, 2026 —
S-8 Employee stock plan registration Feb 26, 2026 —
8-K Current report
Results of operations
Feb 26, 2026 Feb 26, 2026
10-K Annual report Feb 26, 2026 Dec 31, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 5, 2026 —
EFFECT Filing Jan 15, 2026 —
424B3 Prospectus Jan 15, 2026 —
CORRESP Letter to the SEC Jan 13, 2026 —
UPLOAD Letter from the SEC Jan 12, 2026 —
S-1 Registration statement Jan 7, 2026 —
4 Insider transaction Dec 17, 2025 Dec 15, 2025
4 Insider transaction Dec 17, 2025 Dec 15, 2025
4 Insider transaction Dec 17, 2025 Dec 15, 2025
4 Insider transaction Dec 17, 2025 Dec 15, 2025
4 Insider transaction Dec 17, 2025 Dec 15, 2025
4 Insider transaction Dec 17, 2025 Dec 15, 2025
4 Insider transaction Dec 17, 2025 Dec 15, 2025
4 Insider transaction Dec 17, 2025 Dec 15, 2025
S-4 POS Filing Dec 12, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Dec 11, 2025 —
4 Insider transaction Dec 10, 2025 Dec 8, 2025
4 Insider transaction Dec 10, 2025 Dec 8, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Dec 8, 2025 —
4 Insider transaction Dec 8, 2025 Dec 4, 2025
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
Dec 4, 2025 Dec 2, 2025
S-8 Employee stock plan registration Nov 6, 2025 —
8-A12B/A Filing Nov 6, 2025 —
10-Q Quarterly report Nov 6, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 6, 2025 Nov 6, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Oct 14, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Oct 9, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Aug 20, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
8-K Current report
Results of operations, Officer or director change
Jul 31, 2025 Jul 29, 2025
10-Q Quarterly report Jul 31, 2025 Jun 30, 2025
4 Insider transaction Jul 16, 2025 Jul 16, 2025
3 Initial insider ownership Jul 15, 2025 Jul 7, 2025
SCHEDULE 13G Ownership over 5% (passive) Jul 8, 2025 —
3 Initial insider ownership Jun 30, 2025 Jun 13, 2025
3 Initial insider ownership Jun 30, 2025 Jun 13, 2025
4 Insider transaction Jun 23, 2025 Jun 23, 2025
4 Insider transaction Jun 23, 2025 Jun 23, 2025
4 Insider transaction Jun 23, 2025 Jun 23, 2025
4 Insider transaction Jun 23, 2025 Jun 23, 2025
4 Insider transaction Jun 23, 2025 Jun 23, 2025
SCHEDULE 13D Ownership over 5% (active) Jun 23, 2025 —
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
3 Initial insider ownership Jun 23, 2025 Jun 13, 2025
SCHEDULE 13G Ownership over 5% (passive) Jun 23, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Jun 20, 2025 —
8-K Current report
Material agreement, Acquisition or sale of assets, Results of operations, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
Jun 18, 2025 Jun 13, 2025
4 Insider transaction Jun 17, 2025 Jun 13, 2025
8-K Current report
Shareholder vote results, Regulation FD disclosure, Other events
Jun 6, 2025 Jun 5, 2025
425 Filing May 30, 2025 —
8-K Current report
Other events
May 30, 2025 May 30, 2025
425 Filing May 29, 2025 —
SEC STAFF LETTER Filing May 14, 2025 —
EFFECT Filing May 14, 2025 —
10-Q Quarterly report May 14, 2025 Mar 31, 2025
424B3 Prospectus May 14, 2025 —
CORRESP Letter to the SEC May 13, 2025 —
CORRESP Letter to the SEC May 12, 2025 —
S-4/A Filing May 12, 2025 —
UPLOAD Letter from the SEC May 8, 2025 —
S-4/A Filing Apr 29, 2025 —
425 Filing Apr 29, 2025 —
8-K Current report
Material agreement
Apr 29, 2025 Apr 28, 2025
CORRESP Letter to the SEC Apr 28, 2025 —
425 Filing Apr 28, 2025 —
UPLOAD Letter from the SEC Apr 22, 2025 —
CORRESP Letter to the SEC Apr 4, 2025 —
CORRESP Letter to the SEC Apr 4, 2025 —
S-4/A Form s-4/a Apr 4, 2025 —
425 Filing Apr 3, 2025 —
425 Filing Apr 3, 2025 —
SEC STAFF LETTER Filing Mar 18, 2025 —
UPLOAD Letter from the SEC Mar 17, 2025 —
425 Filing Feb 28, 2025 —
425 Filing Feb 27, 2025 —
425 Filing Feb 25, 2025 —
8-K Current report
Agreement ended, Officer or director change
Feb 25, 2025 Feb 19, 2025
S-4 Registration for a merger or exchange Feb 18, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 14, 2025 —
425 Filing Feb 14, 2025 —
8-K Current report
Material agreement
Feb 14, 2025 Feb 14, 2025
10-K Annual report Feb 13, 2025 Dec 31, 2024
8-K Current report
Officer or director change
Jan 31, 2025 Jan 29, 2025
DEFA14A Additional proxy material Jan 13, 2025 —
8-K Current report
Regulation FD disclosure
Jan 13, 2025 Jan 13, 2025
8-K Current report
Listing notice
Dec 26, 2024 Dec 19, 2024
SC 13G Ownership over 5% (passive) Nov 27, 2024 —
10-Q Quarterly report Nov 13, 2024 Sep 30, 2024
SC 13G/A Amended ownership over 5% (passive) Nov 12, 2024 —
DEFA14A Additional proxy material Nov 7, 2024 —
8-K Current report
Regulation FD disclosure
Nov 7, 2024 Nov 7, 2024
SC 13G Ownership over 5% (passive) Nov 6, 2024 —
SC 13D Ownership over 5% (active) Nov 4, 2024 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 4, 2024 —
DEFA14A Additional proxy material Oct 29, 2024 —
8-K Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure, Other events
Oct 29, 2024 Oct 28, 2024
SC 13G/A Amended ownership over 5% (passive) Aug 15, 2024 —
SCHEDULE 13G Ownership over 5% (passive) Aug 14, 2024 —
4 Insider transaction Aug 9, 2024 Aug 7, 2024
10-Q Quarterly report Aug 8, 2024 Jun 30, 2024
4 Insider transaction Aug 7, 2024 Aug 5, 2024
4 Insider transaction Aug 5, 2024 Aug 1, 2024
4 Insider transaction Jul 30, 2024 Jul 26, 2024
8-K Current report
Exit or restructuring costs, Officer or director change, Regulation FD disclosure
Jul 30, 2024 Jul 24, 2024
SC 13G/A Amended ownership over 5% (passive) Jul 29, 2024 —
3 Initial insider ownership Jul 29, 2024 Jul 25, 2024
8-K Current report
Listing notice
Jun 26, 2024 Jun 21, 2024
4 Insider transaction Jun 24, 2024 Jun 20, 2024
4 Insider transaction Jun 20, 2024 Jun 18, 2024
8-K Current report
Officer or director change
Jun 13, 2024 Jun 10, 2024
8-K Current report
Regulation FD disclosure
Jun 4, 2024 Jun 4, 2024
10-Q Quarterly report May 9, 2024 Mar 31, 2024
SC 13D/A Amended ownership over 5% (active) May 8, 2024 —
8-K Current report
Results of operations, Regulation FD disclosure
May 6, 2024 May 6, 2024
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
May 2, 2024 May 1, 2024
4 Insider transaction May 1, 2024 May 1, 2024
4 Insider transaction May 1, 2024 May 1, 2024
4 Insider transaction May 1, 2024 May 1, 2024
4 Insider transaction May 1, 2024 May 1, 2024
4 Insider transaction May 1, 2024 May 1, 2024
4 Insider transaction May 1, 2024 May 1, 2024
4 Insider transaction May 1, 2024 May 1, 2024
4 Insider transaction Apr 2, 2024 Mar 29, 2024
4 Insider transaction Apr 2, 2024 Mar 29, 2023
4 Insider transaction Apr 2, 2024 Mar 29, 2024
ARS Annual report to shareholders Apr 1, 2024 Dec 31, 2023
DEF 14A Proxy statement Apr 1, 2024 May 1, 2024
S-8 Employee stock plan registration Mar 27, 2024 —
8-K Current report
Results of operations
Mar 27, 2024 Mar 27, 2024
10-K Annual report Mar 27, 2024 Dec 31, 2023
PRE 14A Preliminary proxy statement Mar 22, 2024 May 1, 2024

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CBIO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Waltham, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1253689
Former names
GLYCOMIMETICS INC (until Jun 23, 2025)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.